Business

In a striking move, the Federal Trade Commission (FTC) has announced its intent to sue PepsiCo for allegations of illegal price discrimination. This lawsuit centers around the claim that PepsiCo provided more favorable pricing and promotional allowances to a specific retailer compared to its competitors. Unofficial reports indicate that Walmart is the retailer in question,
0 Comments
On a significant day for agricultural innovation and consumer rights, the Federal Trade Commission (FTC) has initiated a lawsuit against Deere & Company. This landmark case centers around allegations of monopolistic practices that are purportedly stifling competition and inflating costs for the farmers who rely on Deere’s agricultural equipment. The issue at stake echoes broader
0 Comments
In recent discussions, JPMorgan Chase executives have openly addressed the challenge posed by an accumulating surplus of capital amounting to an impressive $35 billion. This situation, as articulated by CFO Jeremy Barnum, presents what he refers to as a “high-class problem,” indicating that while an extensive cash reserve can be an asset, it also raises
0 Comments
Eli Lilly’s recent adjustment in revenue guidance has stirred the pharmaceutical landscape, especially concerning its much-talked-about diabetes and weight loss treatments, Mounjaro and Zepbound. On Tuesday, the company revealed a downward revision of its revenue expectations for 2024, projecting approximately $45 billion instead of the previously anticipated figures of $45.4 billion to $46 billion. This
0 Comments
The early reports from major retailers have painted a complex picture of this year’s holiday shopping season. Although some companies like Lululemon and Abercrombie & Fitch showcased stronger than anticipated results, their shares plummeted, demonstrating a disconnect between better-than-expected sales figures and investor sentiment. As retailers release their sales data, it becomes imperative to analyze
0 Comments
The recent news from the Centers for Medicare & Medicaid Services (CMS) that Eli Lilly’s obesity treatment, Zepbound, is now eligible for coverage under Medicare plans marks a significant shift in the landscape of obesity treatment accessibility. Until now, Zepbound, despite its skyrocketing demand and landmark price tag exceeding $1,000, had faced substantial hurdles in
0 Comments